177 related articles for article (PubMed ID: 31049958)
1. CD markers variations in chronic lymphocytic leukemia: New insights into prognosis.
Vosoughi T; Bagheri M; Hosseinzadeh M; Ehsanpour A; Davari N; Saki N
J Cell Physiol; 2019 Nov; 234(11):19420-19439. PubMed ID: 31049958
[TBL] [Abstract][Full Text] [Related]
2. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.
Filip AA; Ciseł B; Wąsik-Szczepanek E
Clin Exp Med; 2015 Feb; 15(1):73-83. PubMed ID: 24337970
[TBL] [Abstract][Full Text] [Related]
3. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.
Huang PY; Best OG; Almazi JG; Belov L; Davis ZA; Majid A; Dyer MJ; Pascovici D; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2014 Sep; 55(9):2085-92. PubMed ID: 24289109
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.
Francia di Celle P; Mariani S; Riera L; Stacchini A; Reato G; Foa R
Blood; 1996 May; 87(10):4382-9. PubMed ID: 8639799
[TBL] [Abstract][Full Text] [Related]
5. Combination of CD160 and CD200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B-cell neoplasms.
Lesesve JF; Tardy S; Frotscher B; Latger-Cannard V; Feugier P; De Carvalho Bittencourt M
Int J Lab Hematol; 2015 Aug; 37(4):486-94. PubMed ID: 25470765
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
7. Developing Molecular Signatures for Chronic Lymphocytic Leukemia.
Cornet E; Debliquis A; Rimelen V; Civic N; Docquier M; Troussard X; Drénou B; Matthes T
PLoS One; 2015; 10(6):e0128990. PubMed ID: 26046539
[TBL] [Abstract][Full Text] [Related]
8. Surface profiles for subclassification of chronic lymphocytic leukemia.
Huang PY; Best OG; Belov L; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2012 Jun; 53(6):1046-56. PubMed ID: 22023531
[TBL] [Abstract][Full Text] [Related]
9. Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia.
Abousamra NK; Salah El-Din M; Hamza Elzahaf E; Esmael ME
Leuk Lymphoma; 2015 Jan; 56(1):113-9. PubMed ID: 24684231
[TBL] [Abstract][Full Text] [Related]
10. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia.
Pulte D; Olson KE; Broekman MJ; Islam N; Ballard HS; Furman RR; Olson AE; Marcus AJ
J Transl Med; 2007 May; 5():23. PubMed ID: 17480228
[TBL] [Abstract][Full Text] [Related]
11. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia.
Visone R; Veronese A; Balatti V; Croce CM
Oncotarget; 2012 Feb; 3(2):195-202. PubMed ID: 22350310
[TBL] [Abstract][Full Text] [Related]
12. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the expression of CD32 and CD180 receptors on CLL cells and MEC1 cell line.
Tsertsvadze T; Mitskevich N; Ghirdaladze D; Porakishvili N
Georgian Med News; 2015 Mar; (240):56-9. PubMed ID: 25879560
[TBL] [Abstract][Full Text] [Related]
14. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.
Bueso-Ramos CE; Ferrajoli A; Medeiros LJ; Keating MJ; Estrov Z
Hematology; 2004 Aug; 9(4):279-86. PubMed ID: 15621735
[TBL] [Abstract][Full Text] [Related]
15. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
[TBL] [Abstract][Full Text] [Related]
16. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of T-cell-associated markers CD4 and CD7 on B-cell chronic lymphocytic leukemia.
Jani P; Qi XY; Chang H
Am J Hematol; 2007 Jan; 82(1):73-6. PubMed ID: 17019687
[TBL] [Abstract][Full Text] [Related]
18. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
[TBL] [Abstract][Full Text] [Related]
19. Aberrant CD8 expression in B-chronic lymphocytic leukemia: report of five cases.
Parisi-Duchêne E; Mazurier I; Moskovtchenko P
Acta Haematol; 2006; 115(1-2):74-7. PubMed ID: 16424654
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
Morabito F; Mangiola M; Rapezzi D; Zupo S; Oliva BM; Ferraris AM; Spriano M; Rossi E; Stelitano C; Callea V; Cutrona G; Ferrarini M
Haematologica; 2003 Aug; 88(8):864-73. PubMed ID: 12935974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
